Results 171 to 180 of about 97,289 (321)

Late‐Onset Spondyloarthritis Presenting as Glucocorticoid‐Resistant Polymyalgia Rheumatica: A Hitherto Underappreciated Entity in Which Tumor Necrosis Factor or Interleukin ‐17 Blockade May Have a Therapeutic Role

Arthritis &Rheumatology, Volume 78, Issue 1, Page 131-140, January 2026.
Objective Polymyalgia rheumatica (PMR) is an age‐related inflammatory disease with shoulder/hip girdle involvement. Magnetic resonance imaging (MRI) reveals extracapsular/entheseal soft tissue involvement in both PMR and spondyloarthritis (SpA), with sacroiliac joint and perientheseal spinal bone marrow edema (BME) being characteristic of SpA ...
Kerem Abacar, Gabriele De Marco, Jake Weddell, Katya Meridor, Tom Macleod, Andrew Scarsbrook, Kulveer Mankia, Edward Vital, Andrew Barr, Colin Pease, Helena Marzo‐Ortega, Sarah L. Mackie, Dennis McGonagle   +12 more
wiley   +1 more source

Prediction Model for Factors Associated With Long‐Term Opioid Use Following Total Knee Arthroplasty: A Retrospective Population‐Based Study

European Journal of Pain, Volume 30, Issue 1, January 2026.
ABSTRACT Background Knee osteoarthritis (OA) affects approximately 10% of the general population. Of these, nearly 20% of patients undergo total knee arthroplasty (TKA). A proportion subsequently develops long‐term opioid use, yet comprehensive evaluations of perioperative risk factors remain limited. Methods A total of 15,051 patients with knee OA who
Pin‐Hung Yeh, Shun‐Fa Yang, Jing‐Yang Huang, Chao‐Bin Yeh   +3 more
wiley   +1 more source

Clinical and Biochemical Factors Associated With Infliximab Pharmacokinetics in Adult Patients With Inflammatory Bowel Disease

The Journal of Clinical Pharmacology, Volume 66, Issue 1, January 2026.
Abstract Many patients with inflammatory bowel disease (IBD) do not adequately respond to infliximab, potentially due to individual differences in pharmacokinetics (PK). This study aimed to identify clinical and biochemical variables associated with infliximab PK.
Ilse A. Pool, Ilse Volkerink, Mirthe Stavast, Jos G. W. Kosterink, Gerard Dijkstra, Paola Mian, Arno R. Bourgonje   +6 more
wiley   +1 more source

Ankylosing spondylitis. [PDF]

BMJ, 1962
openaire   +3 more sources

Epiglottic Ulceration as an Initial Manifestation of Crohn's Disease

Journal of General and Family Medicine, Volume 27, Issue 1, January 2026.
ABSTRACT Crohn's disease can present with various extraintestinal symptoms; however, laryngeal involvement, particularly epiglottic ulcers, is rare. A 52‐year‐old man presented with a sore throat. Laryngeal endoscopy revealed an epiglottic ulcer. He had no gastrointestinal symptoms.
Niina Yamashita, Yoshiki Morihisa, Hiroaki Nishioka   +2 more
wiley   +1 more source

Case of Secondary Amyloidosis in a Patient with Ankylosing Spondylitis Refractory to TNF-α Inhibitors [PDF]

, 2014
Minjin Lee, Seung‐Geun Lee, Eunkyoung Park, Sun-Mi Jang, Sungmin Baek, Geun-Am Song, Geun-Tae Kim   +6 more
openalex   +1 more source

Patterns of complementary and alternative medicine use in pediatric patients with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition, Volume 82, Issue 1, Page 84-92, January 2026.
Abstract Objectives Inflammatory bowel disease (IBD) constitutes a challenging and long‐lasting burden for pediatric patients. The management of IBD is multifaceted involving conventional medication but also dietary measures. An increasing number of patients are turning to complementary and alternative medicine (CAM) in their quest to alleviate IBD ...
Katharina Guilcher, Valerie Pittet, André Moser, Laetitia‐Marie Petit, Klaas Heyland, Christian Braegger, Andreas Nydegger, Luca Garzoni, Susanne Schibli, Johannes Spalinger, Franziska Righini‐Grunder, Christiane Sokollik, the Swiss IBD Cohort Study Investigators   +12 more
wiley   +1 more source

The cataract response in Radium-224 patients [PDF]

, 1989
Chmelevsky, D., Kellerer, Albrecht M., Mays, C. W., Spiess, H., Stefani, F.-H., Taylor, David M.   +5 more
core   +1 more source

Pharmacokinetic Model Selection for Personalized Infliximab Dosing in IBD

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 1, January 2026.
ABSTRACT Infliximab, a monoclonal antibody used for immune‐mediated diseases, shows high interpatient pharmacokinetic variability. Prolonged exposure increases the risk of adverse effects and costs, making dose personalization essential to balance safety, efficacy, and cost‐effectiveness. Population pharmacokinetic models support individualized dosing,
Sahira Chaiben, Peggy Gandia, Thibaut Jamme, Nicolas Congy, Didier Concordet   +4 more
wiley   +1 more source

Beyond HLA-B27: Changing Paradigms in the Genetics of Ankylosing Spondylitis

, 2017
Parikshaa Gupta, Ranjana W. Minz
openalex   +1 more source